Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 17 Years.
Phase of Trial: Phase III
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Pharmacodynamics
- Acronyms FLU-D-PAN-H1N1-010
- 10 Dec 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 10 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.